|
|
Volumn 134, Issue 12, 2007, Pages 982-986
|
|
Efalizumab: Raptiva®;Éfalizumab: Raptiva®
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EFALIZUMAB;
ISONIAZID PLUS RIFAMPICIN;
METHOTREXATE;
RETINOID;
MONOCLONAL ANTIBODY;
ALKALINE PHOSPHATASE BLOOD LEVEL;
ARTHRITIS;
ARTICLE;
ASEPTIC MENINGITIS;
ASTHENIA;
ATOPIC DERMATITIS;
CANCER RISK;
DOSIMETRY;
DRUG CONTRAINDICATION;
DRUG COST;
DRUG ERUPTION;
DRUG FEVER;
DRUG HYPERSENSITIVITY;
DRUG INDICATION;
DRUG MECHANISM;
DRUG UTILIZATION;
EVALUATION;
HEMOLYTIC ANEMIA;
HUMAN;
INFECTION;
INJECTION SITE REACTION;
LEUKOCYTOSIS;
LICHEN PLANUS;
LYMPHOCYTOSIS;
MYALGIA;
NAUSEA;
NEURITIS;
NEUROTOXICITY;
PHOTOTHERAPY;
PSORIASIS;
SIDE EFFECT;
SKIN DISEASE;
SURGICAL INFECTION;
T LYMPHOCYTE;
THROMBOCYTOPENIA;
URTICARIA;
VACCINATION;
VOMITING;
ANTIBODIES, MONOCLONAL;
HUMANS;
PSORIASIS;
|
|
EID: 38049160448
PISSN: 01519638
EISSN: None
Source Type: Journal
DOI: 10.1016/S0151-9638(07)78262-5 Document Type: Article |
|
Times cited : (1)
|
|
References (1)
|
